Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Choroid Plexus Tumor; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Papillary Meningioma; Pineal Gland Astrocytoma; Pineoblastoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsor: City of Hope Medical Center
Not yet recruiting - verified March 2010
Condition: Vestibular Schwannoma
Intervention: Drug: Bevacizumab (Avastin)
Sponsor: Weill Medical College of Cornell University
Not yet recruiting - verified March 2010
Condition: Malignant Glioma
Intervention: Biological: Cancer vaccine plus immune adjuvant, plus activated killer T cells
Sponsor: TVAX Biomedical
Not yet recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Malignant Paraganglioma
Interventions: Drug: temozolomide; Drug: vorinostat; Genetic: DNA methylation analysis; Genetic: western blotting; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Condition: Glioblastoma Multiforme
Interventions: Drug: APG101; Procedure: Blood drawing
Sponsor: Apogenix GmbH
Recruiting - verified March 2010
Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsor: Exelixis
Not yet recruiting - verified February 2010
Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: Trastuzumab or Lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Conditions: Brain Tumor; Intracranial Pressure
Interventions: Drug: Mannitol; Drug: Mannitol
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Not yet recruiting - verified February 2010
Conditions: Severe Traumatic Brain Injury; Head Injury Severe; Traumatic Brain Injury; Brain Injuries
Interventions: Device: Parenchymal Intracranial pressure monitor; Other: Treatment based on clinical and imaging observations
Sponsor: University of Washington
Recruiting - verified February 2010
Condition: Ataxia Telangiectasia
Interventions: Biological: Prevenar® (7-valent pneumococcal conjugate vaccine); Biological: Pneumovax® (pneumococcal polysaccharide vaccine)
Sponsor: Sheba Medical Center
Not yet recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: temozolomide; Other: placebo; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Epilepsy; Tuberous Sclerosis Complex
Intervention: Drug: Everolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Novartis
Not yet recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Liver Metastases; Liver Cancer
Intervention: Biological: rRp450
Sponsors: Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Cannabis; Dependence; Cannabis Abuse; Pharmacokinetics; fMRI
Interventions: Drug: Sativex(Registered Trademark); Drug: THC
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2009
Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: fluorescence in situ hybridization; Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Hedgehog antagonist GDC-0449; Procedure: therapeutic conventional surgery
Sponsor: National Cancer Institute (NCI)
Not yet recruiting - verified January 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsor: National Cancer Institute (NCI)
Not yet recruiting - verified January 2010
Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Procedure: Radiotherapy; Procedure: Radiotherapy; Drug: BIBW2992; Drug: BIBW2992; Drug: Temozolomide
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Condition: Supratentorial Brain Surgery
Intervention: Procedure: Bilateral Scalp Nerve Blocks
Sponsors: St. Michael's Hospital, Toronto; The Physicians' Services Incorporated Foundation
Recruiting - verified February 2010
Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Conditions: Primary Glial Neoplasms of Brain; Glioblastoma
Interventions: Drug: Aminolevulinic Acid; Drug: Aminolevulinic Acid
Sponsors: West Penn Allegheny Health System; DUSA Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Radiation: WBRT; Drug: systemic therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma
Interventions: Drug: XL184; Drug: temozolomide; Drug: temozolomide; Radiation: Radiation Therapy; Drug: temozolomide
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Retinoblastoma
Interventions: Drug: subtenon Carboplatin; Drug: Topotecan Hydrochloride; Drug: Vincristine; Drug: Filgrastim
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2010
Condition: Glioblastoma Multiforme
Interventions: Device: Stealth Station; Device: PoleStar N20
Sponsor: Maastricht University Medical Center
Recruiting - verified March 2010
Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Neoplastic Meningitis
Interventions: Drug: DepoCyt; Drug: Sorafenib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting - verified February 2010
Conditions: Glioblastoma Multiforme; Malignant Gliomas; Anaplastic Gliomas
Intervention: Drug: Sutent (sunitinib)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: MET tyrosine kinase inhibitor PF-02341066; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: Dasatinib; Drug: Lomustine
Sponsors: Bristol-Myers Squibb; European Organization for Research and Treatment of Cancer
Recruiting - verified December 2009
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
Condition: Non-CNS Solid Tumors
Intervention: Biological: HSV1716
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Glioblastoma Multiforme
Intervention: Drug: Azixa
Sponsor: Myriad Pharmaceuticals
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: dasatinib; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Intervention: Drug: doxorubicinhydrochloride, Lapatinib
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; GlaxoSmithKline
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Behavioral: Cognitive Rehabilitation (open); Behavioral: Neurofeedback Training (randomized)
Sponsors: Stanford University; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Conditions: Hot Flashes; Menopause; Vasomotor Symptoms
Interventions: Drug: Escitalopram; Other: Placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Institute on Aging (NIA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Complementary and Alternative Medicine (NCCAM); Office of Research on Women's Health (ORWH)
Active, not recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Brain Cancer; Gliomas
Intervention: Radiation: [18F]FACBC PET and [18F]FLT PET imaging
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Hedgehog antagonist GDC-0449; Genetic: gene expression analysis; Genetic: in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Brain Tumors
Intervention: Procedure: Tissue Banking
Sponsor: University of Florida
Recruiting - verified February 2010
Conditions: Brain Cancer; Central Nervous System Diseases
Interventions: Drug: DELTA-24-RGD-4C; Procedure: Tumor Removal
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: dasatinib; Drug: etoposide phosphate; Drug: ifosfamide; Genetic: microarray analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: High Grade Glioma; Glioblastoma
Intervention: Device: PoleStar N20 intraoperative MRI
Sponsor: Maastricht University Medical Center
Active, not recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: paclitaxel; Drug: carboplatin; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Brain Tumor; Glioblastoma
Intervention: Procedure: MRI/MRS Scan
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Condition: Anaplastic Astrocytoma
Interventions: Drug: trabedersen; Drug: temozolomide or carmustine for infusion; Device: Drug delivery system for administration of AP 12009; Procedure: Placement of Drug Delivery System
Sponsor: Antisense Pharma
Recruiting - verified February 2010
Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Conditions: Brain Tumors; Leukemia; Sarcomas; Neuroblastoma; Lymphoma; Hodgkins Disease
Interventions: Other: Aromatherapy Scented Wand; Other: Placebo wand
Sponsors: Montefiore Medical Center; Soothing Scents, Inc.
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: aminolevulinic acid
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Metastatic Cancer; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: Temozolomide; Procedure: Radiation Therapy
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: Temozolomide; Drug: Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Schering-Plough
Recruiting - verified February 2010
Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
Condition: Hyponatremia
Intervention: Drug: Conivaptan
Sponsors: Northwestern University; Astellas Pharma US, Inc.
Terminated - verified March 2010
Conditions: Glioblastoma; Glioma; Astrocytoma
Interventions: Drug: Temozolomide; Radiation: Radiotherapy
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Lymphoma; Neurotoxicity
Interventions: Biological: rituximab; Drug: cytarabine; Drug: methotrexate; Drug: motexafin gadolinium; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Robert H. Lurie Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Drug: temozolomide; Drug: vorinostat; Procedure: adjuvant therapy; Procedure: cognitive assessment; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: aflibercept; Drug: temozolomide; Genetic: DNA methylation analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsor: National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain Tumor
Intervention: Procedure: Speckle-Contrast Imaging
Sponsors: M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: PEP-3-KLH conjugate vaccine; Biological: daclizumab; Drug: temozolomide; Other: placebo
Sponsors: Duke University; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Steroids
Sponsors: Bristol-Myers Squibb; Medarex
Active, not recruiting - verified July 2009
Conditions: Breast Neoplasm; Brain Neoplasm; Second Neoplasm
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Intrathoracic Malignancies; Unilateral Vocal Cord Paralysis
Interventions: Other: voice evaluation and fMRI; Other: undergo voice evaluation and fMRI prior
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Conditions: CNS Cancer; CNS BRAIN
Intervention: Drug: temozolomide followed by high dose busulfan and thiotepa
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Calgary; Northwestern University; Northwestern Memorial Hospital; University of Wisconsin, Madison; Massachusetts General Hospital
Recruiting - verified March 2010
Condition: Pediatric Cancers
Intervention: Procedure: Carotid Ultrasound
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Suspicion of, or Known Breast Cancer
Intervention: Other: Radiology/MRI scan
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Recurrent Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: irinotecan hydrochloride
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid sequencing; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: computed tomography; Procedure: single photon emission computed tomography; Radiation: 3-dimensional conformal radiation therapy; Radiation: fludeoxyglucose F 18; Radiation: intensity-modulated radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain Neoplasms; Melanoma
Interventions: Drug: Lomustine; Drug: Temozolomide; Drug: Thalidomide
Sponsors: M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified March 2010
Condition: Metastatic Brain Cancer
Intervention: Drug: GLIADEL
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Conditions: Neoplastic Meningitis; Solid Tumor; Lymphoma; Leukemia; Brain Tumor
Intervention: Drug: RTA 744
Sponsors: M.D. Anderson Cancer Center; Reata Pharmaceuticals, Inc.
Active, not recruiting - verified February 2010
Condition: Glioma
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Polymyalgia Rheumatica
Interventions: Drug: Etanercept (Enbrel); Drug: Sodium chloride (placebo)
Sponsor: Bispebjerg Hospital
Completed - verified February 2010
Conditions: Hypothyroidism; Brain Tumor
Interventions: Drug: Levothyroxine; Drug: Liothyronine
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: pazopanib hydrochloride
Sponsors: North American Brain Tumor Consortium; National Cancer Institute (NCI)
Completed - verified October 2008
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: vandetanib
Sponsors: St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab; Drug: cediranib maleate; Genetic: TdT-mediated dUTP nick end labeling assay; Other: flow cytometry; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Glioblastoma Multiforme; Gliosarcoma
Interventions: Drug: ZD6474; Drug: temozolomide; Radiation: Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; University of Virginia; Memorial Sloan-Kettering Cancer Center; Henry Ford Hospital
Recruiting - verified March 2010
Condition: Brain Metastases
Interventions: Drug: Temozolomide; Drug: Valproic Acid; Procedure: whole brain radiation therapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Schering-Plough
Terminated - verified February 2010
Condition: Advanced Malignant Glioma
Interventions: Drug: AMG 102 at 20 mg/kg; Drug: AMG 102 at 10 mg/kg
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: immunologic technique; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: lapatinib plus capecitabine; Drug: lapatinib plus topotecan
Sponsor: GlaxoSmithKline
Terminated - verified February 2010
Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Multiple Sclerosis; Transverse Myelitis; Neuromyelitis Optica; Acute Disseminated Encephalomyelitis; Optic Neuritis
Intervention:
Sponsor: Accelerated Cure Project for Multiple Sclerosis
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsor: Robert H. Lurie Cancer Center
Recruiting - verified July 2009
Conditions: Non Small Cell Lung Cancer; Small Cell Lung Cancer
Interventions: Drug: enzastaurin; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Osteoarthritis; Osteosarcoma; Scoliosis; Cerebral Palsy
Intervention:
Sponsor: University of Florida
Recruiting - verified February 2010
Condition: Brain Metastases From Non-small Cell Lung Cancer
Intervention: Drug: HYCAMTIN, oral capsules
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Metastatic Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity
Interventions: Drug: donepezil hydrochloride; Other: placebo
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Completed - verified February 2010
Condition: Glioma
Intervention:
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Procedure: music therapy; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: temsirolimus; Other: pharmacological study; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Conditions: Drug/Agent Toxicity by Tissue/Organ; Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: carboplatin; Drug: cytarabine; Drug: mannitol; Drug: methotrexate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Brain and Central Nervous System Tumors; Chordoma; Lymphoma; Metastatic Cancer; Von Hippel-Lindau Syndrome
Interventions: Drug: mannitol; Drug: melphalan
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: vorinostat; Procedure: conventional surgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified March 2010
Conditions: Lung Cancer; Metastatic Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: computed tomography; Procedure: positron emission tomography; Radiation: 11C topotecan; Radiation: fludeoxyglucose F 18
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Conditions: Glioblastoma; Gliomas
Interventions: Drug: Temozolomide; Drug: Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Schering-Plough
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Wilms Tumor; Fibrosarcoma; Carcinoma, Round Cell; Nasopharyngeal Cancer; Brain Tumor, Recurrent
Interventions: Procedure: Myeloablative Chemotherapy; Procedure: Stem Cell Rescue
Sponsor: University of Michigan Cancer Center
Active, not recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: porfimer sodium; Procedure: adjuvant therapy; Procedure: conventional surgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Erlotinib hydrochloride
Sponsor: St. Jude Children's Research Hospital
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Carcinoma of Unknown Primary; Leukemia; Lymphoma; Metastatic Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: topotecan hydrochloride
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2008
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: lapatinib ditosylate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lomustine; Drug: temozolomide; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2008
Conditions: Brain and Central Nervous System Tumors; Metastatic Cancer; Neuroblastoma; Sarcoma
Intervention: Radiation: iodine I 131 monoclonal antibody 8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: forodesine hydrochloride
Sponsor: BioCryst Pharmaceuticals
Completed - verified July 2004
Conditions: Drug/Agent Toxicity by Tissue/Organ; Lymphoma; Thrombocytopenia
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: blood-brain barrier disruption chemotherapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: etoposide phosphate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Metastatic Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Letrozole; Drug: Lapatinib (GW572016)
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Conditions: Melanoma (Skin); Metastatic Cancer
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: imatinib mesylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: diagnostic laboratory biomarker analysis; Other: physiologic testing; Procedure: diagnostic imaging
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2008
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: SarCNU
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Gastrointestinal Stromal Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous/Nonmalignant Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: imatinib mesylate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2008
Condition: Metastatic Cancer
Intervention: Drug: temozolomide
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI); Schering-Plough
Completed - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bleomycin sulfate; Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified September 2003
Condition: Lung Cancer
Intervention: Radiation: radiation therapy
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Terminated - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer; NCIC Clinical Trials Group
Active, not recruiting - verified February 2010
Condition: Metastatic Cancer
Intervention: Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: topotecan hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: filgrastim; Biological: sargramostim; Biological: therapeutic autologous lymphocytes; Drug: O6-benzylguanine; Drug: carmustine; Drug: temozolomide; Procedure: in vitro-treated peripheral blood stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Lymphoma
Interventions: Biological: filgrastim; Drug: lomustine; Drug: procarbazine hydrochloride; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
All Categories ... by Medical Condition » ... Cancers » ... Brain Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
